Maximum Views Reached

You have reached the maximum number of Guideline views for today. By creating a free account, you can increase your number of complimentary daily views.

To view this Guideline, please log in to your account. If you do not have an account, you can create one for free by clicking the button below.

Pharmacologic Management of Chronic Obstructive Pulmonary Disease

Publication Date: April 1, 2020

Last Updated: July 31, 2023

Treatment

In patients with COPD who complain of dyspnea or exercise intolerance, the ATS₂ recommends long-acting β-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy. ( S )

Pharmacologic Management of Chronic Obstructive Pulmonary Disease

Treatment

Video

Overview

Title

Authoring Organization